# Misael Uribe

#### List of Publications by Citations

Source: https://exaly.com/author-pdf/5513347/misael-uribe-publications-by-citations.pdf

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

137 papers

4,326 citations

36 h-index 60 g-index

148 ext. papers

4,981 ext. citations

avg, IF

5.3 L-index

#	Paper	IF	Citations
137	Role of oxidative stress and molecular changes in liver fibrosis: a review. <i>Current Medicinal Chemistry</i> , <b>2012</b> , 19, 4850-60	4.3	310
136	The nutritional management of hepatic encephalopathy in patients with cirrhosis: International Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus. <i>Hepatology</i> , <b>2013</b> , 58, 325-36	11.2	239
135	Bariatric surgery for non-alcoholic steatohepatitis in obese patients. <i>The Cochrane Library</i> , <b>2010</b> , CD007	′3 <del>≾</del> 10	159
134	Meta-analysis: antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding - an updated Cochrane review. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2011</b> , 34, 509-18	6.1	152
133	Prevalence of non alcoholic fatty liver disease in premenopausal, posmenopausal and polycystic ovary syndrome women. The role of estrogens. <i>Annals of Hepatology</i> , <b>2010</b> , 9, 402-409	3.1	143
132	Current concepts in the pathogenesis of nonalcoholic fatty liver disease. <i>Liver International</i> , <b>2007</b> , 27, 423-33	7.9	127
131	Metabolic syndrome as a risk factor for gallstone disease. <i>World Journal of Gastroenterology</i> , <b>2005</b> , 11, 1653-7	5.6	124
130	Effect of ezetimibe on the prevention and dissolution of cholesterol gallstones. <i>Gastroenterology</i> , <b>2008</b> , 134, 2101-10	13.3	118
129	The Role of Bile Acids in Glucose Metabolism and Their Relation with Diabetes. <i>Annals of Hepatology</i> , <b>2017</b> , 16, 16-21	3.1	106
128	The prevalence of nonalcoholic fatty liver disease in the Americas. <i>Annals of Hepatology</i> , <b>2014</b> , 13, 166-	138	89
127	Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding. <i>The Cochrane Library</i> , <b>2010</b> , CD002907	5.2	75
126	Imaging techniques for assessing hepatic fat content in nonalcoholic fatty liver disease. <i>Annals of Hepatology</i> , <b>2008</b> , 7, 212-220	3.1	75
125	Role of bioactive fatty acids in nonalcoholic fatty liver disease. <i>Nutrition Journal</i> , <b>2016</b> , 15, 72	4.3	69
124	Variation of the gene encoding the nuclear bile salt receptor FXR and gallstone susceptibility in mice and humans. <i>Journal of Hepatology</i> , <b>2008</b> , 48, 116-24	13.4	68
123	Strong association between gallstones and cardiovascular disease. <i>American Journal of Gastroenterology</i> , <b>2005</b> , 100, 827-30	0.7	64
122	The role of bariatric surgery in the management of nonalcoholic fatty liver disease and metabolic syndrome. <i>Metabolism: Clinical and Experimental</i> , <b>2016</b> , 65, 1196-207	12.7	62
121	A systematic review and meta-analysis of the use of oral zinc in the treatment of hepatic encephalopathy. <i>Nutrition Journal</i> , <b>2013</b> , 12, 74	4.3	59

120	In vivo 3T spectroscopic quantification of liver fat content in nonalcoholic fatty liver disease: Correlation with biochemical method and morphometry. <i>Journal of Hepatology</i> , <b>2010</b> , 53, 732-7	13.4	59
119	Endocannabinoid receptor CB2 in nonalcoholic fatty liver disease. <i>Liver International</i> , <b>2007</b> , 27, 215-9	7.9	59
118	Etiology of Liver Cirrhosis in Mexico. <i>Annals of Hepatology</i> , <b>2004</b> , 3, 30-33	3.1	59
117	Trends in liver disease prevalence in Mexico from 2005 to 2050 through mortality data. <i>Annals of Hepatology</i> , <b>2005</b> , 4, 52-55	3.1	59
116	High coffee intake is associated with lower grade nonalcoholic fatty liver disease: the role of peripheral antioxidant activity. <i>Annals of Hepatology</i> , <b>2012</b> , 11, 350-355	3.1	58
115	Role of diet in cholesterol gallstone formation. <i>Clinica Chimica Acta</i> , <b>2007</b> , 376, 1-8	6.2	56
114	Prevalence of metabolic syndrome, obesity and diabetes type 2 in cryptogenic cirrhosis. <i>World Journal of Gastroenterology</i> , <b>2008</b> , 14, 4771-5	5.6	55
113	Clinical and pathologic factors associated with survival in young adult patients with fibrolamellar hepatocarcinoma. <i>BMC Cancer</i> , <b>2005</b> , 5, 142	4.8	54
112	Eosinophilic gastroenteritis: a review. <i>Digestive Diseases and Sciences</i> , <b>2007</b> , 52, 2904-11	4	52
111	The nuclear receptor FXR, but not LXR, up-regulates bile acid transporter expression in non-alcoholic fatty liver disease. <i>Annals of Hepatology</i> , <b>2015</b> , 14, 487-493	3.1	51
110	Anabolic-androgenic steroids and liver injury. Liver International, 2008, 28, 278-82	7.9	50
109	The prevalence of nonalcoholic fatty liver disease in the Americas. <i>Annals of Hepatology</i> , <b>2014</b> , 13, 166-	78.1	49
108	Image-guided percutaneous procedure plus metronidazole versus metronidazole alone for uncomplicated amoebic liver abscess. <i>The Cochrane Library</i> , <b>2009</b> , CD004886	5.2	47
107	Beneficial effect of vegetable protein diet supplemented with psyllium plantago in patients with hepatic encephalopathy and diabetes mellitus. <i>Gastroenterology</i> , <b>1985</b> , 88, 901-7	13.3	47
106	Transcript levels of Toll-Like Receptors 5, 8 and 9 correlate with inflammatory activity in Ulcerative Colitis. <i>BMC Gastroenterology</i> , <b>2011</b> , 11, 138	3	46
105	Weight reduction and ursodeoxycholic acid in subjects with nonalcoholic fatty liver disease. A double-blind, placebo-controlled trial. <i>Annals of Hepatology</i> , <b>2004</b> , 3, 108-112	3.1	45
104	Pregnancy and gallbladder disease: Symposium on liver & pregnancy. <i>Annals of Hepatology</i> , <b>2006</b> , 5, 227	7-3:30	40
103	Prevalence of gallstone disease in Mexico. A necropsy study. <i>Digestive Diseases and Sciences</i> , <b>1993</b> , 38, 680-3	4	40

102	The interplay between hepatic stellate cells and hepatocytes in an in vitro model of NASH. <i>Toxicology in Vitro</i> , <b>2015</b> , 29, 1753-8	3.6	37
101	Adiponectin as a protective factor in hepatic steatosis. World Journal of Gastroenterology, 2005, 11, 173	87 <del>5.4</del> 61	36
100	Association between cholecystectomy for gallstone disease and risk factors for cardiovascular disease. <i>Annals of Hepatology</i> , <b>2012</b> , 11, 85-89	3.1	35
99	Prophylactic activated recombinant factor VII in liver resection and liver transplantation: systematic review and meta-analysis. <i>PLoS ONE</i> , <b>2011</b> , 6, e22581	3.7	34
98	Prevalence of minimal hepatic encephalopathy and quality of life in patients with decompensated cirrhosis. <i>Hepatology Research</i> , <b>2014</b> , 44, E92-9	5.1	32
97	The Amerindian's genes in the Mexican population are associated with development of gallstone disease. <i>American Journal of Gastroenterology</i> , <b>2004</b> , 99, 2166-70	0.7	32
96	Herbal Medicine in Mexico: A Cause of Hepatotoxicity. A Critical Review. <i>International Journal of Molecular Sciences</i> , <b>2016</b> , 17, 235	6.3	32
95	Fish oil (n-3) polyunsaturated fatty acids beneficially affect biliary cholesterol nucleation time in obese women losing weight. <i>Journal of Nutrition</i> , <b>2001</b> , 131, 2300-3	4.1	31
94	Prevalence of hepatitis C virus infection among hemodialysis patients at a tertiary-care hospital in Mexico City, Mexico. <i>Journal of Clinical Microbiology</i> , <b>2004</b> , 42, 4321-2	9.7	30
93	High ghrelin and obestatin levels and low risk of developing fatty liver. <i>Annals of Hepatology</i> , <b>2010</b> , 9, 52-57	3.1	28
92	Common features of the metabolic syndrome and nonalcoholic fatty liver disease. <i>Reviews on Recent Clinical Trials</i> , <b>2014</b> , 9, 148-58	1.2	28
91	Diagnostic accuracy of nodular gastritis for H. pylori infection. <i>Therapeutics and Clinical Risk Management</i> , <b>2017</b> , 13, 9-14	2.9	28
90	Association among C-reactive protein, Fatty liver disease, and cardiovascular risk. <i>Digestive Diseases and Sciences</i> , <b>2007</b> , 52, 2375-9	4	25
89	Endoscopic submucosal dissection in dogs in a World Gastroenterology Organisation training center. <i>World Journal of Gastroenterology</i> , <b>2010</b> , 16, 1759-64	5.6	25
88	Current evidence on the use of probiotics in liver diseases. <i>Journal of Functional Foods</i> , <b>2015</b> , 17, 137-15	55.1	24
87	Mitochondrial Molecular Pathophysiology of Nonalcoholic Fatty Liver Disease: A Proteomics Approach. <i>International Journal of Molecular Sciences</i> , <b>2016</b> , 17, 281	6.3	24
86	Gallstones are associated with carotid atherosclerosis. <i>Liver International</i> , <b>2008</b> , 28, 402-6	7.9	23
85	Nuclear receptors in nonalcoholic Fatty liver disease. <i>Journal of Lipids</i> , <b>2012</b> , 2012, 139875	2.7	22

### (2010-2008)

84	Hepatic expression of ghrelin and adiponectin and their receptors in patients with nonalcoholic fatty liver disease. <i>Annals of Hepatology</i> , <b>2008</b> , 7, 67-71	3.1	22
83	Biomarkers in hepatocellular carcinoma: an overview. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2017</b> , 11, 549-558	4.2	21
82	The role of the gut microbiota in the pathology and prevention of liver disease. <i>Journal of Nutritional Biochemistry</i> , <b>2018</b> , 60, 1-8	6.3	21
81	Less liver fibrosis in metabolically healthy compared with metabolically unhealthy obese patients with non-alcoholic fatty liver disease. <i>Diabetes and Metabolism</i> , <b>2017</b> , 43, 332-337	5.4	20
80	Latin American Association for the Study of the Liver Recommendations on Treatment of Hepatitis C. <i>Annals of Hepatology</i> , <b>2014</b> , 13, S4-S66	3.1	20
79	Hepatobiliary diseases and insulin resistance. Current Medicinal Chemistry, 2007, 14, 1988-99	4.3	20
78	Serum zinc concentrations in two cohorts of 153 healthy subjects and 100 cirrhotic patients from Mexico City. <i>Digestive Diseases</i> , <b>1995</b> , 13, 136-42	3.2	20
77	The Role of Dendritic Cells in Fibrosis Progression in Nonalcoholic Fatty Liver Disease. <i>BioMed Research International</i> , <b>2015</b> , 2015, 768071	3	19
76	Insulin sensitizers in treatment of nonalcoholic fatty liver disease: Systematic review. <i>World Journal of Gastroenterology</i> , <b>2006</b> , 12, 7826-31	5.6	19
75	Liver diseases in Mexico and their associated mortality trends from 2000 to 2007: A retrospective study of the nation and the federal states. <i>Annals of Hepatology</i> , <b>2010</b> , 9, 428-438	3.1	18
74	Risk factors and prevalence of hepatitis virus B and C serum markers among nurses at a tertiary-care hospital in Mexico City, Mexico: a descriptive study. <i>Annals of Hepatology</i> , <b>2006</b> , 5, 276-280	3.1	18
73	Latin American Association for the Study of the Liver (LAASL) Clinical Practice Guidelines: Management of Hepatocellular Carcinoma. <i>Annals of Hepatology</i> , <b>2014</b> , 13, S4-S40	3.1	17
72	Albumin dialysis with molecular adsorbent recirculating system (MARS) for the treatment of hepatic encephalopathy in liver failure. <i>Annals of Hepatology</i> , <b>2011</b> , 10, S70-S76	3.1	17
71	New insights into the pathophysiology of nonalcoholic fatty liver disease. <i>Annals of Hepatology</i> , <b>2009</b> , 8, S9-S17	3.1	17
70	Adiponectin, structure, function and pathophysiological implications in non-alcoholic fatty liver disease. <i>Mini-Reviews in Medicinal Chemistry</i> , <b>2006</b> , 6, 651-6	3.2	17
69	Plasma leptin and the cholesterol saturation of bile are correlated in obese women after weight loss. <i>Journal of Nutrition</i> , <b>2002</b> , 132, 2195-8	4.1	17
68	Hepatic manifestations of metabolic syndrome. Diabetes/Metabolism Research and Reviews, 2013,	7.5	16
67	TLR9 mRNA expression is upregulated in patients with active ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , <b>2010</b> , 16, 1267-8	4.5	15

66	Treating nonalcoholic fatty liver disease. <i>Liver International</i> , <b>2007</b> , 27, 1157-65	7.9	15
65	Serum leptin levels and insulin resistance are associated with gallstone disease in overweight subjects. <i>World Journal of Gastroenterology</i> , <b>2005</b> , 11, 6182-7	5.6	15
64	Trends in liver disease prevalence in Mexico from 2005 to 2050 through mortality data. <i>Annals of Hepatology</i> , <b>2005</b> , 4, 52-5	3.1	15
63	Microscopic colitides: a single center experience in Mexico. <i>International Journal of Colorectal Disease</i> , <b>2007</b> , 22, 1031-6	3	14
62	Etiology of liver cirrhosis in Mexico. <i>Annals of Hepatology</i> , <b>2004</b> , 3, 30-3	3.1	14
61	Factors Associated with the Quality of Transient Elastography. <i>Digestive Diseases and Sciences</i> , <b>2015</b> , 60, 2177-82	4	13
60	Both alcoholic and non-alcoholic steatohepatitis association with cardiovascular risk and liver fibrosis. <i>Alcohol</i> , <b>2018</b> , 69, 63-67	2.7	13
59	Understanding the association of polycystic ovary syndrome and non-alcoholic fatty liver disease. Journal of Steroid Biochemistry and Molecular Biology, <b>2019</b> , 194, 105445	5.1	13
58	IFN-stimulated gene expression is a useful potential molecular marker of response to antiviral treatment with Peg-IFN⊉b and ribavirin in patients with hepatitis C virus genotype 1. <i>Archives of Medical Research</i> , <b>2011</b> , 42, 28-33	6.6	13
57	Role of nonalcoholic fatty liver disease in hepatocellular carcinoma. <i>Annals of Hepatology</i> , <b>2009</b> , 8, S34-	S <u>3</u> 9	13
56	Risk factors for gallstone disease in Mexicans are similar to those found in Mexican-Americans. Digestive Diseases and Sciences, <b>1998</b> , 43, 935-9	4	13
55	The molecular basis of susceptibility to infection in liver cirrhosis. <i>Current Medicinal Chemistry</i> , <b>2007</b> , 14, 2954-8	4.3	13
54	The role of dietary fats in the pathogenesis of gallstones. <i>Frontiers in Bioscience - Landmark</i> , <b>2003</b> , 8, e420-7	2.8	13
53	Learning curve in a Western training center of the circumferential en bloc esophageal endoscopic submucosal dissection in an in vivo animal model. <i>Diagnostic and Therapeutic Endoscopy</i> , <b>2011</b> , 2011, 847831	Ο	12
52	Geographical distribution of HCV genotypes in Mexico. <i>Annals of Hepatology</i> , <b>2007</b> , 6, 156-160	3.1	11
51	The efficacy of adipokines and indices of metabolic syndrome as predictors of severe obesity-related hepatic steatosis. <i>Digestive Diseases and Sciences</i> , <b>2006</b> , 51, 1716-22	4	11
50	Prevalence of hepatitis C infection in a population of asymptomatic people in a checkup unit in Mexico city. <i>Digestive Diseases and Sciences</i> , <b>2005</b> , 50, 733-7	4	11
49	Hypoxic hepatitis in cardiac intensive care unit: a study of cardiovascular risk factors, clinical course, and outcomes. <i>Therapeutics and Clinical Risk Management</i> , <b>2014</b> , 10, 139-45	2.9	10

## (2006-2010)

48	Prevalence of type 2 diabetes mellitus and chronic liver disease: A retrospective study of the association of two increasingly common diseases in Mexico. <i>Annals of Hepatology</i> , <b>2010</b> , 9, 282-288	3.1	10
47	The Role of Epigenetics in the Progression of Non-Alcoholic Fatty Liver Disease. <i>Mini-Reviews in Medicinal Chemistry</i> , <b>2015</b> , 15, 1187-94	3.2	10
46	Impact of anthropometric cut-off values in determining the prevalence of metabolic alterations. <i>European Journal of Clinical Investigation</i> , <b>2016</b> , 46, 940-946	4.6	10
45	Liver toxicity mechanisms of herbs commonly used in Latin America. <i>Drug Metabolism Reviews</i> , <b>2017</b> , 49, 338-356	7	9
44	The management of incidental fatty liver found on imaging. What do we need to do?. <i>American Journal of Gastroenterology</i> , <b>2018</b> , 113, 1274-1276	0.7	9
43	An update on the management of hepatitis C: guidelines for protease inhibitor-based triple therapy from the Latin American Association for the Study of the Liver. <i>Annals of Hepatology</i> , <b>2013</b> , 12, S3-S35	3.1	9
42	High gene expression of MDR1 (ABCB1) is associated with medical treatment response and long-term remission in patients with ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , <b>2010</b> , 16, 541-2	4.5	9
41	A genetic variant in the interleukin 28B gene as a major predictor for sustained virologic response in chronic hepatitis C virus infection. <i>Archives of Medical Research</i> , <b>2015</b> , 46, 448-53	6.6	8
40	Elevated cholesterol levels have a poor prognosis in a cholestasis scenario. <i>Journal of Biochemical and Molecular Toxicology</i> , <b>2017</b> , 31, 1-6	3.4	8
39	Obesity-related leptin receptor polymorphisms and gallstones disease. <i>Annals of Hepatology</i> , <b>2006</b> , 5, 97-102	3.1	8
38	The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. <i>Annals of Internal Medicine</i> , <b>2006</b> , 144, 379; author reply 380	8	8
37	Effects of leptin on biliary lipids: potential consequences for gallstone formation and therapy in obesity. <i>Current Drug Targets Immune, Endocrine and Metabolic Disorders</i> , <b>2005</b> , 5, 203-8		8
36	Association Between Serum Hemoglobin Levels and Non Alcoholic Fatty Liver Disease in a Mexican Population. <i>Annals of Hepatology</i> , <b>2018</b> , 17, 577-584	3.1	8
35	Prevalence of hepatitis C virus infection among patients undergoing haemodialysis in Latin America. <i>Annals of Hepatology</i> , <b>2015</b> , 14, 807-14	3.1	7
34	Importance of iron and iron metabolism in nonalcoholic fatty liver disease. <i>Mini-Reviews in Medicinal Chemistry</i> , <b>2008</b> , 8, 171-4	3.2	7
33	Clinical heterogeneity in autoimmune acute liver failure. World Journal of Gastroenterology, <b>2007</b> , 13, 1824-7	5.6	7
32	Factors that influence outcome in non-invasive and invasive treatment in polycystic liver disease patients. <i>World Journal of Gastroenterology</i> , <b>2008</b> , 14, 3195-200	5.6	6
31	Low serum levels of ghrelin are associated with gallstone disease. <i>World Journal of Gastroenterology</i> , <b>2006</b> , 12, 3096-100	5.6	6

30	Metabolic syndrome and nonalcoholic fatty liver disease. The role of endothelial progenitor cells?. <i>Annals of Hepatology</i> , <b>2013</b> , 12, 908-914	3.1	5
29	Human leukocyte antigens among primary biliary cirrhosis patients born in Mexico. <i>Annals of Hepatology</i> , <b>2009</b> , 8, 32-37	3.1	5
28	Non-alcoholic fatty-liver disease in pediatric populations. <i>Journal of Pediatric Endocrinology and Metabolism</i> , <b>2007</b> , 20, 1059-73	1.6	5
27	The diagnostic and initial approach of the patient with non-alcoholic fatty liver disease: role of the primary care provider. <i>Gastroenterology and Hepatology From Bed To Bench</i> , <b>2019</b> , 12, 267-277	1.2	5
26	Manipulation of microbiota with probiotics as an alternative for treatment of hepatic encephalopathy. <i>Nutrition</i> , <b>2020</b> , 73, 110693	4.8	5
25	Albumin dialysis with molecular adsorbent recirculating system (MARS) for the treatment of hepatic encephalopathy in liver failure. <i>Annals of Hepatology</i> , <b>2011</b> , 10 Suppl 2, S70-6	3.1	5
24	Validation of prognostic scores for clinical outcomes in cirrhotic patients with acute variceal bleeding. <i>Annals of Hepatology</i> , <b>2016</b> , 15, 895-901	3.1	4
23	Metabolic Features of Alcoholic Liver Disease. <i>Reviews on Recent Clinical Trials</i> , <b>2016</b> , 11, 220-6	1.2	4
22	Role of the inflammasome, gasdermin D, and pyroptosis in non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia</i> ), <b>2021</b> , 36, 2720-2727	4	4
21	The utility of the C-methacetin breath test in predicting the long-term survival of patients with decompensated cirrhosis. <i>Journal of Breath Research</i> , <b>2017</b> , 11, 036011	3.1	3
20	Latin American Association for the Study of the Liver Practice Guidelines: Diagnosis, management, and treatment of hepatitis C This document has been approved by the Latin American Association for the Study of the Liver (ALEH). <i>Annals of Hepatology</i> , <b>2010</b> , 9, S8-S26	3.1	3
19	Evaluation of iron overload in healthy adult residents of Mexico City. <i>Archives of Medical Research</i> , <b>2005</b> , 36, 142-7	6.6	3
18	Response to Letter of Guy D. Eslick. American Journal of Gastroenterology, 2005, 100, 2363-2363	0.7	3
17	Cholecystectomy as a risk factor for non-alcoholic fatty liver disease development. <i>Hpb</i> , <b>2020</b> , 22, 1513	-135&20	3
16	Dietary consumption and serum pattern of bioactive fatty acids in NAFLD patients. <i>Annals of Hepatology</i> , <b>2020</b> , 19, 482-488	3.1	3
15	Prevalence in vulnerable population of liver fibrosis identified by transient elastography. <i>Annals of Hepatology</i> , <b>2015</b> , 14, 524-530	3.1	2
14	Metabolic syndrome and estimates of cardiovascular disease in cirrhotic patients. <i>Journal of Digestive Diseases</i> , <b>2008</b> , 9, 149-55	3.3	2
13	Bariatric surgery for non-alcoholic steatohepatitis in obese patients 2008,		2

#### LIST OF PUBLICATIONS

12	Atorvastatin and portal pressure. <i>Hepatology</i> , <b>2007</b> , 46, 1309-10; author reply 1310	11.2	2
11	Hypertransaminasemia and severe hepatic steatosis without inflammation. A case report. <i>Annals of Hepatology</i> , <b>2003</b> , 2, 183-185	3.1	2
10	G protein-coupled receptors: Key molecules in metabolic associated fatty liver disease development. <i>Nutrition Research</i> , <b>2021</b> , 87, 70-79	4	2
9	Assessment of outcomes of hepatitis C treatment. <i>JAMA - Journal of the American Medical Association</i> , <b>2014</b> , 312, 2570-1	27.4	1
8	Hepatocyte transplantation for treating chronic hepatic dysfunction. <i>Journal of Organ Dysfunction</i> , <b>2007</b> , 3, 131-136		1
7	Cerebral hemodynamics in the non-alcoholic fatty liver. <i>Annals of Hepatology</i> , <b>2020</b> , 19, 668-673	3.1	1
6	Hypertransaminasemia and severe hepatic steatosis without inflammation. A case report. <i>Annals of Hepatology</i> , <b>2003</b> , 2, 183-5	3.1	1
5	Nonalcoholic steatohepatitis in chronic hepatitis C: A new classification?. <i>Hepatology</i> , <b>2008</b> , 47, 759; author reply 759-60	11.2	O
4	Laparoscopic cholecystectomy: Histopathological analysis of metabolic associated fatty liver disease and fibrosis <i>Annals of Hepatology</i> , <b>2021</b> , 27, 100651	3.1	O
3	Bioactive lipids in metabolic liver disease. Studies in Natural Products Chemistry, 2021, 263-297	1.5	O
2	Food for Liver Health: Probiotics <b>2019</b> , 387-391		
1	Epidemiological and Genetic Aspects of NAFLD and NASH in Mexico <i>Clinical Liver Disease</i> , <b>2022</b> , 19, 68-72	2.2	